I think that what the thread over the lifetime of the product demonstrates is that "from little things, big things grow" (ack Paul Kelly). To get shelf space in dominant retailers is a great achievement and the resultant sales increase is impressive.
We will see the same progression with NXS clinical products..... a groundswell of adoption by surgeons who are generally conservative....not early adopters. They want evidence based research before they will take professional risks.
I think that what the thread over the lifetime of the product...
Add NXS (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
28.5¢ |
Change
0.010(3.64%) |
Mkt cap ! $83.26M | |||
| Open | High | Low | Value | Volume |
| 27.5¢ | 28.5¢ | 26.5¢ | $50.38K | 184.6K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 6191 | 26.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 28.5¢ | 12524 | 1 |
View Market Depth
| Last trade - 16.10pm 29/07/2024 (20 minute delay) ? |
| NXS (ASX) Chart |